BioSpace Global Roundup

Gecko Biomedical – Paris-based Gecko is rebranding. The privately-owned life science company is changing its name to TISSIUM as part of an overall rebranding of the company. The new name more accurately reflects the company’s mission to develop novel solutions for tissue reconstruction for multiple clinical indications, the company announced. TISSIUM has robust product development and manufacturing capabilities and is able to bring new products to market independently, or in partnership with other industry players. Christophe Bancel, chief executive officer of TISSIUM, said the rebranding was undertaken as part of an opportunity to showcase the company’s platform of biomorphic programmable polymers that are designed to change the way the industry thinks about tissue reconstruction. The rebranding reflects that intent, Bancel said in a statement.
Valbiotis – France-based Valbiotis completed its Phase IIa study of Valedia in pre-diabetic subjects. The results of the study will be presented at a medical conference before July 31, the company said. The international Phase IIA study evaluated the efficacy of TOTUM-63, the active ingredient of Valedia, in reducing one or more of the three risk factors of type 2 diabetes. In addition to these prediabetes results, the study will evaluate other physiological parameters, including, for example, triglyceride regulation or intestinal microbiota composition.